If all things go well, the Pfizer-BioNTech Covid-19 vaccine will receive EUA from the U.S. Food and Drug Administration around December 10 or within a few days after, and the Moderna vaccine will receive EUA around December 17 or within a few days after.
Phase I data from the Covid-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
In order to generate more shots on goal in the development of a vaccine for COVID-19, the U.S. government will provide funds for the development of three vaccine programs against the disease.
Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration narrowed that list to five potential treatments for the prevention of the novel coronavirus.
AstraZeneca and the University of Oxford are partnering on the global development and distribution of Oxford’s COVID-19 vaccine.
There are more than 70 groups worldwide rushing to develop a vaccine against COVID-19, including Moderna, Johnson & Johnson, Pfizer and BioNTech, Novavax and many others. One of the groups that appears to be ahead of the race is not a commercial biopharma company: Oxford University’s Jenner Institute.